NPM1 and myeloproliferative disorder: Interestingly, a model of Dnmt3a-driven CHIP demonstrated that acquiring Npm1 mutations can lead to the development of myeloproliferative disorders (MPD), and additional transplantation leads to AML (SanMiguel et al., 2022).